Insulin sensitisation as a novel mechanism to lessen ischaemic burden in overweight non-diabetic patients with chronic stable angina: a pilot study

Next Previous
Trial Profile

Insulin sensitisation as a novel mechanism to lessen ischaemic burden in overweight non-diabetic patients with chronic stable angina: a pilot study

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 18 Feb 2009

At a glance

  • Drugs Rosiglitazone (Primary)
  • Indications Angina pectoris
  • Focus Therapeutic Use

    • Most Recent Events

    • 18 Feb 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 19 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top